share_log

Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"

Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"

Navidea Biopharmaceuticals已收到其美國專利應用程序17/370,920的許可通知,標題爲 “統一定義的分子量甘露糖化葡聚糖及其衍生物的合成(用於Tilmanocept免疫療法應用)”
Benzinga ·  2023/05/24 15:58

Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"

Navidea Biopharmaceuticals已收到其美國專利應用程序17/370,920的許可通知,標題爲 “統一定義的分子量甘露糖化葡聚糖及其衍生物的合成(用於Tilmanocept免疫療法應用)”

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論